A unique of synthetic methods was employed to prepare 2-(4-methoxyphenyl)-4-phenyl-1,10-phenanthroline (5) derivatives from 4-methoxy-benzaldehyde (1), acetophenone (2), and 8-aminoquinoline (4) with aldol condensation and cyclization reactions. The derivatives were tested through antiplasmodial test. The synthesis of derivatives compound 5 was conducted in three steps. The 3-(4-methoxyphenyl)-1-phenylpropenone 3 was synthesized through aldol condensation of 1 and 2 which has a yield of 96.42%. The compound 5 was synthesized through cyclization of compound 4 and 3 with 84.55% yield. The derivative of compound 5 was synthesized from compound 5 using DMS and DES reagents which refluxed for 21 and 22 h, to produce (1)-N-methyl-9-(4-methoxyphenyl)-7-phenyl-1,10-phenanthrolinium sulfate (6) and (1)-N-ethyl-9-(4-methoxyphenyl)-7-phenyl-1,10-phenanthrolinium sulfate (7) with 91.42 and 86.36% yields, respectively. Results of in vitro testing of antiplasmodial activity of compound 5 derivatives (i.e., compound 6 and 7) against chloroquine-resistant P. falciparum FCR3 strain showed that compound 7 had higher antimalarial activity than compounds 5 and 6. Whereas, results of in vitro testing against chloroquine-sensitive P. falciparum D10 strain showed that compound 6 has higher antimalarial activity than compounds 5 and 7.
Introduction
Nowadays malaria accounts for 1-3 million deaths yearly worldwide, with most of these deaths occurring in children under 5 years. Approximately 3 billions people, one half of the world's population, live in at-risk regions for malaria infections. Malaria is the main health problem in subtropical and tropical countries. This leads to about 250 million malaria cases every year and nearly one million deaths. There are 105 countries in the world with endemic malaria and more than 500 million cases or more than 3 million deaths from malaria each year [1] [2] [3] [4] [5] [6] [7] [8] . Worldwide, the majority of deaths occur in children; other high risk groups include pregnant women, refugees, migrant workers, and non immune travelers − over 20 million Western tourists are at risk annually (fact sheets from Malaria Foundation International). Although four species of the genus Plasmodium cause human malaria, Plasmodium falciparum is the deadliest cause. P. falciparum will be the subject of this review [9] .
Malaria cases are constantly changing, especially through the development of parasite resistant to standard antimalarial drugs such as chloroquine. Chloroquine has been the primary medicine for falciparum malaria chemotherapy for decades: it is cheap, safe, and practicable for outpatient use. Unfortunately, chloroquine resistance is now extensively spreading in some countries, including Indonesia. In Indonesia, malaria remains a health problem especially in eastern Indonesia. In the year 2003 the Annual Parasitemia Incidence (API) was 175.558 cases and the annual malaria incidence was more than 2.48 million and there were 211 deaths among 227.5 million Indonesian people [10] [11] [12] .
Chloroquine resistant has been wide spread at some endemic areas in Indonesia. Base on data from the Indonesian Ministry of Health office in 2003, the annual parasite incidence in Java-Bali was 0.22 per 1000 populations, while the annual malaria incidence in outer Java-Bali was 21.8 per 1000 populations [11] . Therefore, it is essential to find new antimalarial drugs that have higher pharmacological activity compared to current antimalarial drugs. Consequently, Quantitative Structure Activity Relationship (QSAR) analysis plays an important role to minimize trial and error in designing new antimalarial drugs [13] [14] .
Five years ago, our research concerned with the synthesis and biological activity of 1,10-phenanthroline derivatives. In this program follow up, this paper report our results concerning the synthesis and the determination of the biological activity of compound type (1)-N-alkyland (1)-N-benzyl-1,10-phenanthrolinium [11] . Based on the 1,10-phenanthroline skeleton, Mustofa, [15] we have also synthesized thirteen derivatives of 1,10-phenanthroline and evaluated the in vitro antiplasmodial activity and their QSAR. The results of the QSAR analysis found the best theoretical activity of six new compounds and synthesized and evaluated their in vitro antiplasmodial activity through laboratory experiment.
Recently, our research reported the antiplasmodial activity of (1)-N-alkyl-and (1)-N-benzyl-1,10-phenanthrolinium showed that (1)-N-methyl-1,10-phenanthrolinium sulfate, This study synthesized compound 5 derivatives i.e: 6 and 7 compounds (Fig. 1) . A unique of synthetic methods has been employed to prepare 5 derivatives from 1, 3, and 4 compounds with aldol condensation and cyclization reactions.
Methods
Materials. Two strains of chloroquine-resistant P. falciparum, FCR-3 (IC 50 > 100 nM) and chloroquinesensitive, D10 strain (IC 50 < 100 nM) were obtained from Eijkman Institute for Molecular Biology Jakarta, p-methoxybenzaldehyde p.a. 
Characterization of compounds.
In general, the melting point of compounds was determined on melting point electro thermal 9100. The spectrum measurements of compound structures were taken using the following instruments: FTIR spectrums were taken on Shimadzu FTIR-8201 PC; 1 H-NMR spectrums were obtained on JEOL 60 MHz and JEOL 500 MHz MS spectrums were recorded on GC-MS Shimadzu QP 5000 (EI method).
Synthesis of 3-(4-Methoxyphenyl)-1-phenylpropenone (3).
The ethanol (15 ml) was transferred into a 125 ml Erlenmeyer flask, and 20 ml of 10% KOH solution was added. Using a thermometer, the solution was cooled to 20 ºC. In a medium size tube, compound 2 was mixed (2.72 g; 20 mmol) with compound 1 (2.40 g; 20 mmol), and then the mix compound was left at room temperature for 5 minutes. Then, small portions of ethanol-NaOH solution mixture were added and stirred with a magnetic stirrer (if available) for 30 minutes. The mixture was cooled in ice-water bath. The product was filtrated and hand-dried to collect the yellow oils to yield compound 3.
Synthesis of 2-(4-Methoxyphenyl)-4-phenyl-1,10-phenanthroline (5).
The compound 3 (6.13 g; 20 mmol) was added over 6 h to a stirred solution of the compound 4 (1.73 g; 10 mmol) and NaI (12 mmol) in H 2 SO 4 70% (5 ml) at 110 o C. After 1 h at 110 o C the dark brown reaction mixture was cooled at room temperature, added to 1 M Na 2 CO 3 (50 ml) and extracted with CH 2 Cl 2 (3 x 50 ml). The combined organic layers were extracted with CH 2 Cl 2 . Subsequently, the filtrates were evaporated under reduced pressure to yield 1,10-phenanthroline skeleton as a product of reaction. The products were purified by filtration through silica gel using CH 2 Cl 2 as a solvent to produce brown solid of compound 5.
Synthesis of (1)-N-Methyl-9-(4-methoxyphenyl)-7-phenyl-1,10-phenanthrolinium sulfat (6). The compound 6 (0.73 g; 2 mmol) and dimethylsulfate (DMS; 1.26 g, 10 mmol) in acetone (20 ml) were refluxed for 21 hours. The resulting mixture was then cooled. The precipitate which formed was filtered, and washed with acetone and recrystalized with dichloromethane : diethyl ether (1:1). The precipitate which formed was filtered and washed with acetone to produce brown solid of compound 6.
Synthesis of (1)-N-ethyl-9-(4-methoxyphenyl)-7-
phenyl-1,10-phenanthrolinium sulfate (7). The compound 6 (0.73 g; 2 mmol) and diethylsulfate (DES; 1.54 g; 10 mmol) in acetone (25 ml) were refluxed for 22 hours. The resulting mixture was then cooled. The precipitate which formed was filtered, and washed with acetone and recrystalized with dichloromethane : diethyl ether (1:1). The precipitate which formed was filtered and washed with acetone to produce brown solid of compound 8.
Biological Activity. Parasites were cultured according to the modified method described by Trager and Jensen [17] . The parasites were maintained in vitro in human red blood cells (O±), diluted to 1-2% hematocrit in RPMI-1640 medium (Sigma-Aldrich, USA), supplemented with 25 mM HEPES (Sigma Chemical, USA) and 30 mM NaHCO 3 (Sigma-Aldrich, USA) and supplemented with 5% human O± serum. Parasite cultures were synchronized by 5% of D-sorbitol (Sigma-Aldrich, USA) in distilled water as reported by Lambros and Vanderburgh [18] . The method used for in vitro antiplasmodial activity testing was adapted from a radioactive method as described [19] . Strain FCR3 was considered as a chloroquine resistant strain and strain D10 was considered as a chloroquine sensitive strain. The method used for in vitro antimalarial activity testing was adapted from visual method. The moleculer were tested 3 times in triplicate in 96-well plates (TPP, Switzerland) with cultures at ring stage at 0.5-1.0% parasitemia (hematocrit: 1%). For each test, the parasite cultures were incubated with the chemicals at decreasing concentrations for 24 and 72 h. The first dilution of the product (10 mg/ml) was perfomed with dimethylsulfoxide (DMSO, Merck), and the following with RPMI 1640. Parasite growth was estimated by coloring with Giemsa (10%) for 30 seconds and calculated using β-caunter. The parasite control in the presence without chemicals (mean of the corresponding wells was referred to as 100%). Concentrations inhibiting 50% of the parasite (IC 50 ) were determined by SPPS 13.0 software.
Results and Discussion
A unique of synthetic methods was employed to prepare compound 5 derivatives from compounds 2, 1, and 4 with aldol condensation and cyclization reactions. The synthesis of compound 5 derived through three steps (Fig. 1) . The first step was synthesizing of compound 3 by aldol condensation reaction. The second step was synthesizing compound 5 from 4 and 3 through cyclization reaction. The third step was synthesizing the (1)-N-alkyl-9-phenyl-1,10-phenantrolinium salts derivative from compound 5 using DMS and DES as reagent to produce compounds 6 and 7, respectively ( Figure 1 ).
Compound 3-(4-Methoxyphenyl)-1-phenylpropenone (3).
The synthesis of compound 3 was conducted through condensation reaction using the NaOH as base catalyst. The condensation of compound 1 and 2 to produce compound 3 as a product of reaction The product of condensation reaction was characterized by FTIR, 1 H-NMR and mass spectrometry. The FTIR spectrum showed the peaks at ύ 1629.5 and 1527.9/cm these indicated that the product of condensation reaction had C=C bonding from aromatic group. Absorption bands of C=O, C-H sp3 , and C-O at ύ 1700.1, 1377.1, and 1161.1/cm, respectively corroborated the existence of the compound 3 as a product of this reaction. In the 1 H-NMR spectrum, compound 3 did not have signals at 10-13 ppm, which indicates no aldehyde group (-CHO) existed. Mass spectrometry spectrum, showed the peak of molecular ion at m/z 238 which indicated the presence compound 3. The result of the FTIR, 1 H-NMR and mass spectrum of compound 3 is showed in Figure  2 and 3, respectively.
Compound 2-(4-Methoxyphenyl)-4-phenyl-1,10-phenanthroline (5).
The synthesis of compound 5 was conducted from compound 4 and 3 through cyclization reaction using NaI and H 2 SO 4 70% as the catalyst. The product of cyclization reaction was characterized by FTIR, 1 H-NMR and mass spectrometry. The products were purified by filtration through silica gel using CH 2 The structure of compound 6 was determined by FTIR and 1 H-NMR spectrum (Figure 6 and 7) . The FTIR spectrum showed typical spectra at 1369. 4 C sp2 -H The typical spectra in ύ 1461.9 /cm of the FTIR spectrum ( Figure 8 Intensity benzyloxy-3-methoxybenzyl-1,10-phenanthrolinium chloride compounds. In another compound, Hadanu [12] reported the activities of one new compound of (1)-N-(4-methoxybenzyl-1,10-phenanthrolinium bromide. In all compounds tested for antiplasmodial activities, the (1)-N-benzyl-1,10-phenanthrolinium bromide showed the highest activity (0.10±0.13 µM) against P. falciparum strain FCR3, whereas the (1)-N-benzyl-1,10-phenanthrolinium bromide showed the highest activity (IC 50 : 0.33±0.34 µM) on P. falciparum strain D10.
In this research, the result of antiplasmodial activities using chloroquine-resistant strain FCR-3 was summarized in Table 1 . Meanwhile, the result of investigation antiplasmodial activities using chloroquine sensitive strain D10 was summarized in Table 2 . In this study, the antiplasmodial activity of 1,10-phenanthroline derivatives showed that compounds 5, 6 and 7 were active against P. falciparum strain FCR3 with an IC 50 1.28±0.05, 0.16±0.05, and 0.07±0.01 µM, respectively and strain D10 with an IC 50 0.55±0.07, 0.01±0.01, and 0.03±0.01 µM, respectively. The result of antiplasmodium evaluation to all of 5 compound derivatives toward strain FCR-3 and strain D10 of P. falciparum were presented in Table 1 and 2, completely. Based on the result presented in Table 1 and 2, the compound 7 (IC 50 : 0.07±0.01 µM) has highest antiplasmodial activity in strain FCR-3, while the compound 6 (IC 50 : 0.01±0.01µM) has the highest antiplasmodial activity in the D10 strain. 2) . Although the suppression of parasitemia was never complete (100% inhibition of parasite growth), the results indicated antiplasmodial potential. In the P. falciparum strain FCR3, the compound 7 had higher activity than compounds 6 and 5, but in the P. falciparum strain D10, the compound 6 had higher activity than compounds 7 and 5.
Conclusions
Three derivative compounds of 1,10-phenanthroline i.e. compounds 5, 6 and 7 were successfully obtained in this study by a unique of synthetic methods. Results of in vitro antiplasmodial activity of these compounds on chloroquine-resistant P. falciparum strain FCR-3 showed that compound 7 has the highest antiplasmodial activity which is equal to 0.07±0.01 µM. However, the highest activity on chloroquine-sensitive strain D10 was exhibited by the compound 6, i.e equal to 0.01±0.01 µM.
